Salma Sharaf

Salma Sharaf

Auto-generated profile, based on publicly available information

Salma Sharaf

Institute of Human Virology University of Maryland School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2026 in HIV Medicine
Verified
Journal Article
Open access
GLGuangming Li
Guangming Li
SSSalma Sharaf
Salma Sharaf
YLYaoxian Lou
Yaoxian Lou
Lishan SuLishan Su
Lishan Su
SKShyam Kottilil
Shyam Kottilil
PMPoonam Mathur
Poonam Mathur
Objectives: HIV perturbs T cell homeostasis and disrupts immune function, increasing the risk of age‐associated comorbidities. Ageing people with HIV (PWH) have exacerbated expression of CD38 on T cells, which depletes intracellular nicotinamide adenine dinucleotide (NAD+). We investigated whether boosting intracellular NAD+ could restore T cell homeostasis and function. Methods: We collected blood samples from virally suppressed PWH to determine the effects of in vitro NAD+ on CD38 expression and T cell function in response to anti‐CD3/CD28 antibodies stimulation in PBMCs culture supplemented with IL‐2 and IL‐7. Results: We observed that NAD+ supplementation not only reduced expression of CD38 but also improved T cell function with an alleviated exhaustion phenotype in response to anti‐CD3/CD28 antibodies stimulation. Conclusions: If confirmed in clinical trials, NAD+ supplementation has the potential to restore T cell homeostasis and immune function in PWH and ameliorate age‐associated comorbidities.

27 July 2026 in Journal of Medical Virology
Verified
Journal Article
Open access
TPTetiana Pozniak
Tetiana Pozniak
SSSalma Sharaf
Salma Sharaf
CGChloe Gross
Chloe Gross
EEEmade Ebah
Emade Ebah
AKArshi Khanam
Arshi Khanam
AGAlip Ghosh
Alip Ghosh
Direct‐acting antiviral (DAA) drugs lead to sustained virologic response (SVR) in almost all treated patients with chronic hepatitis C virus (HCV) infection. Despite this success, the long‐term effects of HCV clearance by DAA therapy on T‐cell‐mediated antiviral immunity remain unclear, particularly concerning the restoration of immune function and its role in providing subsequent protection against reinfection. Our results demonstrated enhanced HCV‐specific cytokine production by CD4 + T cells in vitro, particularly in the activated CD38 + and CD38 + HLADR + subsets 1 year after DAA‐mediated cure with increased frequencies of TNF‐α + , IFNγ + TNF‐α + , IL‐2 + , and IL‐21 + cells. Notably, these subsets also exhibited reduced expressions of inhibitory markers, PD1 and TIGIT. Furthermore, reduced mitochondrial reactive oxygen species production and increased mitochondrial membrane potential were observed in CD38 + T helper cells, suggesting improved mitochondrial function. Significant reductions in serum IP‐10, MIP‐1β, and TNF‐α levels were observed, indicating decreased systemic inflammation. These findings suggest that DAA‐mediated HCV cure partially restores T helper cell function through reduced expression of inhibitory markers and improved mitochondrial activity in a subset of chronic HCV patients 1 year after SVR, which may potentially enhance immune protection and reduce the risk of reinfection.